Substantial Triglyceride Reduction With Plozasiran : compare

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

Related Keywords

Georgia , United States , Canada , Montreal , Quebec , North Carolina , Atlanta , Neha Pagidipati , Daniel Gaudet , University Of Montreal , American College Of Cardiology Annual Scientific Session , Duke Clinical Research Institute , American College , Annual Scientific Session , Lipids , Ipid Management , Triglycerides , Cv Risk , Cardiovascular Risk , V Risk Factors , Cardiovascular Risk Factors , Cardiovascular Risk Management , Abdominal Infection , Pancreatitis , Hypertriglyceridemia Hypertriglyceridaemia , Acute Pancreatitis , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Coronary Artery Disease ,